AbbVie Inc.
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Robert A. Michael
- Full Time Employees
- 50,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 North Waukegan Road North Chicago IL United States of America 60064-6400
- IPO Date
- Jan 2, 2013
- CIK
- 0001551152
- Website
- abbvie.com
- Similar Companies
- Business
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Company News
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Undervalued Dividend Kings: October 2024
3 Magnificent Dividend Stocks to Buy in October
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
AbbVie cuts 2024 profit forecast on R&D expenses
AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia
3 Top Pharma Stocks to Buy in October 2024
AbbVie: A Strong Investment Opportunity In Neurological And Oncology Breakthroughs
Dividend Stocks With Strong Q4 Seasonality
AbbVie: $200 Peak (Rating Downgrade)
AbbVie's Skyrizi And Rinvoq Deserve The Premium Growth Valuation
Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
5 Best Dividend Growth Stocks to Buy in October
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
EU withdraws marketing authorisation for Abbvie's hepatitis C drug
AbbVie to Host Third-Quarter 2024 Earnings Conference Call